P
Pierian Biosciences
A privately held life sciences company offering the development and delivery of innovative, treatment-directing information
About Pierian Biosciences
Pierian Biosciences, established in 2008 and formerly known as DiaTech Oncology, is a privately held life sciences company headquartered in Franklin, Tennessee. The company operates as a diagnostic development and laboratory service provider, focusing on personalized cancer intelligence to guide treatment decisions for patients with cancer and autoimmune diseases. Robert Henry joined the company as CEO in 2013, bringing over 25 years of healthcare management experience to steer the company's growth in the personalized cancer care market. A significant milestone in the company's history is its international expansion, which involved establishing its first UK laboratory in Liverpool's Science Park in October 2022, a project involving over £60 million in investment. This strategic move was designed to foster collaboration with key medical opinion leaders and access the UK's research facilities, with Chief Scientific Officer Norman Purvis relocating to manage the new site.
The company's business model is centered on providing clinically actionable diagnostic information to healthcare providers. It serves biopharmaceutical companies and clinicians, offering support from pre-clinical research through Phase IV clinical trials. Revenue is generated through its laboratory and diagnostic services that help personalize treatment strategies, aiming to improve patient outcomes and lower healthcare costs. Pierian Biosciences has secured substantial funding to support its operations and growth, raising a total of $76.2 million over three rounds, including a significant Series C funding of $75 million in 2015.
Pierian Biosciences' core offerings are its advanced technology platforms: ChemoINTEL™ and ImmunoINTEL™. The ChemoINTEL™ platform is a chemosensitivity assay that measures the real-time apoptotic response of a patient's isolated tumor cells to various cytotoxic agents and targeted therapies. This platform utilizes an automated, high-throughput imaging system to provide a single-cell functional analysis, helping to identify the most effective chemotherapy drugs for an individual. The ImmunoINTEL™ platform is a flow cytometry-based system that provides a detailed characterization of the tumor microenvironment and the immune landscape. It quantifies tumor and immune cell populations and analyzes their functional status, which is crucial for guiding the selection of immunotherapies. Together, these platforms support the development of personalized treatment plans by determining which therapeutic agents are most likely to be effective against a specific patient's cancer.
Source: Dealroom company dataNews
Open roles
Pierian Biosciences in the Franklin ecosystem
The Pierian Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pierian Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pierian Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

